{"denoms":[{"counts":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"86"},{"groupId":"BG002","value":"168"}],"units":"Participants"}],"groups":[{"description":"The subject received the PEGASYS at a dose level of 45 micrograms weekly and gradually increased to the maximum dose of 180 micrograms per week. The dose was administered by prefilled syringes and injected subcutaneously. Subjects received therapy for up to 12 months.\n\nAspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.","id":"BG000","title":"PEGASYS"},{"description":"Subjects received a 500mg tablet to be taken twice daily for up to 12 months of treatment.\n\nAspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.","id":"BG001","title":"Hydroxyurea"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.8","value":"56.8"},{"groupId":"BG001","spread":"12.8","value":"61.8"},{"groupId":"BG002","spread":"14.0","value":"59.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"70"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"98"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"146"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"11"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"98"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age > 60 years","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"137"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"28"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}],"title":"3+"}],"description":"The ECOG measures level of functioning in terms of daily living abilities:\n\n0-Fully active, able to carry on all pre-disease performance without restriction\n\n1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg.light house work\n2. Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about \\>50% of waking hours\n3. Capable of only limited selfcare; confined to bed or chair \\>50% of waking hours\n4. Completely disabled; cannot carry on any selfcare; totally confined to bed or chair\n5. Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"The Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"81"}]}],"title":"Essential thrombocythemia (ET)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"87"}]}],"title":"Polycythemia Vera (PV)"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Type","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"46"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Previous Thrombosis","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Previous Hemorrhage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Splenomegaly","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0","upperLimit":"41.7","value":"2.6"},{"groupId":"BG001","lowerLimit":"0","upperLimit":"84.2","value":"3.0"},{"groupId":"BG002","lowerLimit":"0","upperLimit":"84.2","value":"2.8"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Disease Duration","unitOfMeasure":"months"}]}